Odronextamab
As of the edition of 20 October 2026, Odronextamab is an antibody: marketed, first approved in 2024 (EU); acts on CD3D, CD3E and CD3G and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2024
- Kind
- Antibody
- Brand name
- Ordspono
- First approved
- 22 August 2024 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Regeneron
- Registered trials
- 16, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Pregnancy and women's health; Skin and connective tissue; Urinary and reproductive
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company-target row on route B because of this drug.
Companies on route B for this drug
In the product1 company-target row is on route B because of Odronextamab.
See the 1 company-target row on route B for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 0 |
| Phase 1 | 5 | 2 | 3 | 0 |
| Phase 2 | 4 | 0 | 4 | 0 |
| Phase 3 | 6 | 0 | 6 | 0 |
| All trials | 16 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Regeneron | Applicant and Lead sponsor of trials | 2023 to now |